Company Overview - BlissBio Inc. (百力司康) submitted its prospectus for listing on the Hong Kong Stock Exchange, with Goldman Sachs, Huatai International, and Jianyin International as joint sponsors [1] - The company was founded on December 7, 2017, by Wei Ziping and Zhou Yuhong, and operates under the name BlissBio Biopharmaceutical (Hangzhou) Co., Ltd. [3] Financial Information - The registered capital of BlissBio Biopharmaceutical (Hangzhou) Co., Ltd. is RMB 1.931661 million, down from RMB 2.814294 million due to a recent capital reduction [3][4] - The company has undergone five rounds of domestic financing from 2018 to 2023, raising RMB 35 million in the angel round, RMB 110 million in the A round, RMB 435 million in the B round, RMB 123.8 million in the B+ round, and RMB 170 million in the B++ round [5][6] Shareholding Structure - As of now, Wei Ziping holds 15.71% of the shares, Zhou Yuhong holds 10.48%, and they collectively hold 8.01% through PartnerBio Corporation [6] - Other significant shareholders include Hillhouse Capital, which holds 11.70%, and Dongfang Fuhai with 11.55% [8] Product Pipeline - BlissBio is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address unmet needs in cancer treatment [8] - The core product, BB-1701, is an HER2-targeted ADC candidate primarily aimed at breast cancer and non-small cell lung cancer [8][9] - The company has three additional ADC candidates in clinical stages: BB-1705 (EGFR ADC), BB-1712 (anti-B7-H3 ADC), and BB-1709 (CD73 ADC) [9] Revenue and Losses - BlissBio reported revenues of approximately RMB 180.2 million in 2023, which is expected to drop by 87.5% to about RMB 22.6 million in 2024, primarily due to a one-time milestone payment in 2023 [10] - The net losses for 2023 and 2024 are projected to be approximately RMB 206.4 million and RMB 556.6 million, respectively, totaling around RMB 760 million [11]
百力司康闯关港交所上市,已完成五轮融资,两年亏损7.6亿元
Sou Hu Cai Jing·2025-06-29 14:32